Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T19:59:18.825Z.
Calculation as of: 2026-10-06T19:59:18.825Z.
Quote observation: 2026-10-06T19:54:31.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 1639651ea08d8a43111aa8341d4d68762a5dc33ecadd1da8a92c037613eb041e
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$48.76M
EV/EBIT Ratio
N/A
TTM Avg
36.45x
3Y Avg
39.02x
5Y Avg
39.02x
Market Cap
$49.06M
EV/EBIT Ratio
N/A
TTM Avg
11.96x
3Y Avg
9.90x
5Y Avg
11.19x
Market Cap
$49.58M
EV/EBIT Ratio
N/A
TTM Avg
398.45x
3Y Avg
398.45x
5Y Avg
398.45x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Instil Bio, Inc. (TIL) | $47.27M | N/A | N/A | N/A | N/A |
| Lite Strategy, Inc. (LITS)vs › | $47.98M | N/A | N/A | N/A | N/A |
| Microbot Medical Inc. (MBOT)vs › | $48.76M | N/A | 36.45x | 39.02x | 39.02x |
| Apollomics, Inc. (APLM)vs › | $47.59M | N/A | N/A | N/A | N/A |
| TELA Bio, Inc. (TELA)vs › | $48.99M | N/A | N/A | N/A | N/A |
| Sensus Healthcare, Inc. (SRTS)vs › | $49.06M | N/A | 11.96x | 9.90x | 11.19x |
| Celularity Inc. (CELU)vs › | $45.73M | N/A | N/A | N/A | N/A |
| INmune Bio, Inc. (INMB)vs › | $49.71M | N/A | N/A | N/A | N/A |
| Precision Optics Corporation, Inc. (POCI)vs › | $49.58M | N/A | 398.45x | 398.45x | 398.45x |
| Werewolf Therapeutics, Inc. (HOWL)vs › | $44.72M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
